# Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

> **NCT01649765** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 93 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Belimumab 10 mg/kg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01649765
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-07
- **Primary completion:** 2018-01-24
- **Final completion:** 2025-09-30
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01649765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01649765, "Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01649765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*